StockWatch
·

Tinna Trade Ltd Q2 FY27 Results

FRATELLIQ2 FY27 Results
Filing
Result:Poor· Market: Flat#Margin squeeze

Outlook: Negative · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue45.241.2%1.4%
Total Income46.753.0%0.7%
Expenditure53.075.4%4.4%
PBT-6.3227.4%42.6%
Net Profit-6.3272.5%90.7%
OPM-3.27%3.93pp4.98pp
NPM-13.52%5.44pp6.38pp
EPS-1.10230.9%244.7%
View full financials

Revenue was flat YoY but the core wine-manufacturing segment's operating loss widened for a third straight quarter, flipping EBITDA margin negative (-3.27% vs +1.71% a year ago) and deepening the net loss on rising debt-driven finance costs — a clear deterioration, not a turnaround.

FRATELLI VINEYARDS · Q2 FY-27 · THE VERDICT

RTD Momentum Masks a Broken Profit Model

Fratelli doubled RTD cases to nearly 100,000, but Q2 flat revenue and ₹6.3 crore net loss expose the flaw: EBITDA breakeven plus high debt means no path to profit until FY28 at earliest. Management has abandoned prior guidance and is now managing down expectations.

16 Nov 2026 · 6 min read
Q2 Reported PAT

-₹6.3 Cr

-90.7% YoY

H1 EBITDA

₹1.4 Cr

1.5% margin

D&A + Interest (est.)

~₹2 Cr/qtr

Eating profit despite EBITDA breakeven

The surface narrative is RTD momentum: Shotgun doubled to nearly 100,000 cases in H1, revenue ₹18 crore (from ₹8.5 crore prior). But beneath that sits a harder truth—the income statement doesn't reconcile. H1 EBITDA is ₹1.4 crore, yet Q2 net loss is ₹6.3 crore. The gap is a high debt burden: roughly ₹1–2 crore per quarter in interest and D&A. For a ₹45 crore revenue quarter on the edge of flat growth, that math breaks.

Management's claims—what holds up

Reality-check of key on-call narratives

Shotgun RTD is on track; 100k cases achieved, heading to 200k FY27

Confirmed. H1 RTD ~100k cases, revenue ₹18 Cr (doubled from ₹8.5 Cr prior year). Distribution footprint (32k touchpoints) supports volume ambition.

Supported

EBITDA improved; H1 moved from loss ₹1 Cr to profit ₹1.4 Cr

Confirmed on EBITDA; but Q2 net loss ₹6.3 Cr shows D&A/interest burden ~₹2 Cr/qtr is material. EBITDA breakeven does not translate to profit.

Supported (on EBITDA); misleading for profit

Gross margin guidance 77–80% remains intact

Q2 gross margin fell to 76.7% due to RTD mix (RTD at ~76% vs premium 80%+). RTD is ~40% of revenue now. Guidance claim is at odds with Q2 result and current mix.

Overstated

Revenue growth is on track; H1 up 10%

H1 +10% is real, but Q2 flat (-1.4% YoY). Momentum stalled. Growth is RTD (emerging category) not core wine (down in premium/UP market).

Supported on H1; contradicted on momentum

Net profitability expected Q1/Q2 FY28, not FY27

Implies full FY27 remains loss-making. Management de facto abandoned prior implicit target of FY27 recovery. Profitability timeline slipped ~18 months.

Candid; signals execution miss vs prior calls

What changed from prior quarters

  • Profitability timeline slipped: FY27 recovery → FY28 Q1/Q2 (~18 months delayed)

  • EBITDA margin guidance abandoned: Prior 10–12% FY27 target → now 1.5% H1, no reaffirmed forecast

  • RTD strategy crystallized: Shotgun now ~40% of revenue at 76% margin (vs premium 80%+)

  • Excise policy headwinds extended: UP (key market) down 30% H1, not contained to Q1

  • Cash flow stress acknowledged: ₹18 Cr VAT refund stuck; rights issue (₹29.87 Cr) raised to ease debt

The bull-bear ledger

  • RTD is real growth: 100k cases in H1, doubled in 6 months, on track to 200k FY27. New occasion, younger consumers.

  • Luxury (JNOON) holds pricing power: +23% H1 despite excise headwinds. Brand equity intact.

  • International expansion credible: 18 countries (4 new in H1); TASMAC Tamil Nadu, Jammu/Kashmir on roadmap.

  • Distribution moat is real: 32,000 retail touchpoints; 65% HoReCa revenue, strong channel position.

  • BUT: Q2 flat revenue (-1.4% YoY) breaks the growth narrative. RTD gains offset by core wine decline (UP down 30%).

  • BUT: Gross margin compressed 230bp due to RTD mix. RTD at 76% margin vs 80%+ premium; marketing spend 9–10% of RTD sales inflates opex.

  • BUT: PAT loss ₹6.3 Cr on flat revenue. High D&A/interest burden (~₹2 Cr/qtr) breaks profit despite EBITDA breakeven.

  • BUT: Cash flow remains tight (₹5 Cr H1) despite EBITDA profit. Inventory buildup, ₹18 Cr VAT stuck, high DSO—working capital drain.

  • BUT: Prior 10–12% EBITDA margin guidance far off-track (now 1.5%). Management deferring FY27 guidance to Q3, signaling low confidence.

  • BUT: Regulatory risk is structural. UP down 30%; recovery timing unclear. Premium segment most exposed.

How the street is positioned

At ₹107.1 (as of Nov 13), Fratelli is down 78% from its all-time high of ₹494.8 but holding above its 200-day average (₹99.53). The stock sits 9.7% below its 20-day SMA (₹118.36), signaling recent weakness but not capitulation. RSI at 33.7 is neutral—not oversold. Volume is normal. The market has priced in pain, but not total loss of faith.

Ownership is flat. FII hold 0.48%, DII 0%, and promoters 57.19%—no meaningful institutional flow QoQ. This is a retail/promoter-held story, not one attracting institutional capital. The absence of FII/DII buying on a 78% drawdown suggests institutions are waiting for a clearer path to profitability before committing. Promoters are holding steady (no recent exits), which is a mild positive—they haven't abandoned ship.

Risks ranked (by how much they should concern a holder)

The things that can break this thesis, ordered by severity

Profitability slip: FY28 breakeven misses or slips to FY29

High

Management has already slipped from FY27 to FY28. If FY28 execution stumbles (RTD scaling, margin recovery, debt paydown), credibility collapses and stock re-rates lower.

Regulatory headwinds (excise policy) persist or worsen

High

UP (key market) down 30% H1 due to excise policy. If Q3/Q4 show no relief and other states follow, revenue base shrinks further. Premium segment most exposed.

RTD profitability unproven; unit economics opaque

High

RTD margin ~76% (vs 80%+ premium). Marketing spend 9–10% of RTD sales is high. If RTD becomes >50% of revenue and margin doesn't recover, blended margin declines further.

Cash flow remains tight; debt service constrains capex

High

H1 operating CF only ₹5 Cr despite EBITDA ₹1.4 Cr. Inventory buildup, ₹18 Cr VAT stuck, DSO high. Rights issue (₹29.87 Cr) will help, but working capital recovery takes 2–3 quarters.

Gross margin doesn't recover to 79–80% as RTD scales

Medium

If RTD margin stays at 76% and volume grows, blended margin can only decline. CFO claims margin will 'normalize' but no timeline or evidence provided.

Import competition post India-EU FTA pressures premium pricing

Medium

FTA duty reductions (imported wines to 150% from prior) could increase availability. Pricing pressure on premium segment (JNOON, Sette) is a tail risk.

What to watch next (catalysts over 2–3 quarters)

The things that resolve the debate
  • 1 · Q3 FY27 guidance revision (expected soon)

    Management deferred full-year revenue/margin guidance to Q3. The Nov-Jan update will signal confidence (raised) or caution (held/lowered). If guidance is again lowered or deferred, credibility collapses.

  • 2 · TASMAC Tamil Nadu rollout and RTD ramp (Q3/Q4)

    Shotgun enters Tamil Nadu TASMAC next quarter; also rolling out ethnic flavors. These are needle-movers for RTD volume. Acceleration toward 200k cases by year-end would validate the strategy.

  • 3 · Operating CF recovery and debt trajectory (H2 FY27)

    Rights issue (₹29.87 Cr) closes by January 2027. VAT refunds (₹18 Cr stuck) expected 'next year or so.' If working capital improves and operating CF rises to ₹10–15 Cr/qtr, debt paydown becomes credible and FY28 profitability thesis gains traction.

The honest read

Fratelli is in the middle of a strategic pivot—RTD is real, luxury is intact, and distribution is world-class. But the near-term profit math is broken, and management has missed its prior targets by a wide margin. The 10–12% EBITDA margin guidance for FY27 is now abandoned; H1 shows 1.5%. Profitability is delayed to FY28 at best.

This is not a step-change in the business. It's a company navigating a regulatory headwind (UP excise), executing a product pivot (RTD), and trying to escape a debt burden (₹2 Cr interest/qtr). Each is solvable. But they're moving in different directions—new product pulls margin down, regulatory headwind pulls revenue down, and debt pulls profit down.

At ₹107.1, the stock has priced in a lot of pain (down 78% from ATH). The debate is no longer 'will this work?' but 'will it work fast enough?' If FY28 Q1/Q2 shows net profit breakeven and RTD cases hit 150k+, the thesis works. If profitability slips to FY29 or RTD plateaus below 150k, the stock re-rates lower.

For a current holder, this is a Hold. The thesis is intact, but it's a 'show me' story now. For a buyer, wait for Q3 guidance (expected soon) or early FY28 signals before stepping in. The single number to track: operating cash flow. If H1 ₹5 Cr grows to ₹10–15 Cr/qtr by year-end (post rights issue and VAT refund), that's the green light. If it stays flat or declines, the debt spiral continues and the FY28 breakeven thesis falters.

Informational and educational content only. Not investment advice.